The Verona Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
What was Verona Pharma’s price range in the past 12 months?
Verona Pharma lowest stock price was $4.40 and its highest was $15.71 in the past 12 months.
What is Verona Pharma’s market cap?
Verona Pharma’s market cap is $422.01M.
What is Verona Pharma’s price target?
The average price target for Verona Pharma is $20.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $25.00 ,the lowest forecast is $17.00. The average price target represents 174.73% Increase from the current price of $7.28.
What do analysts say about Verona Pharma?
Verona Pharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
When is Verona Pharma’s upcoming earnings report date?
Verona Pharma’s upcoming earnings report date is Aug 10, 2021 which is next month.
How were Verona Pharma’s earnings last quarter?
Verona Pharma released its earnings results on Apr 29, 2021. The company reported -$0.364 earnings per share for the quarter, beating the consensus estimate of -$0.474 by $0.11.
Is Verona Pharma overvalued?
According to Wall Street analysts Verona Pharma’s price is currently Undervalued.
Does Verona Pharma pay dividends?
Verona Pharma does not currently pay dividends.
What is Verona Pharma’s EPS estimate?
Verona Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verona Pharma have?
Verona Pharma has 57,970,000 shares outstanding.
What happened to Verona Pharma’s price movement after its last earnings report?
Verona Pharma reported an EPS of -$0.364 in its last earnings report, beating expectations of -$0.474. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Verona Pharma?
Among the largest hedge funds holding Verona Pharma’s share is RA Capital Management. It holds Verona Pharma’s shares valued at 43M.